Purchase this article with an account.
Sung Jae Yang, Ju Byung Chae, Young Hee Yoon, Joo Yong Lee, June-Gone Kim; Intravitreal Bevacizumab for the Treatment of Diabetic Papillopathy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3898.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To present the effect of intravitreal bavacizumab injection for the treatment of diabetic papillopathy.
Retrospectively reviewed the medical records of 3 consecutive patients who treated with intravitreal injection of bevacizumab for the treatment of diabetic papillopathy.
Patient one was a 73-year-old woman with 15-year history of type II diabetes mellitus, her vision of left eye improved from 0.05 to 0.32 6 weeks after intravitreal bevacizumab injection. Patient two was a 47-year-old woman with 8-year history of type II diabetes mellitus, her vision of right eye was 0.16. A week after intravitreal injection of bevacizumab, vision impoved to 0.32. Patient three was a 46-year-old woman with 2-year history of type II diabetes mellitus. Her vision of left eye was 0.63. Two week after injection her vision was improved to 0.8. One month after injection blurring of disc margin disappeared. There were resolution of disc swelling and/or leakage from fluorescein angiography within 2~6 weeks in all three cases. There was no injection related complication.
The visual acuity of all the three patients improved within few weeks. Intravitreal bevacizumab injection for the treatment of diabetic papillopathy seems effective and safe. And intravitreal bevacizumab injection can be one of options for the treatment of diabetic papillopathy and shortened the duration of symptom.
This PDF is available to Subscribers Only